A testosterone replacement therapy (TRT) evaluation covers more ground than a single lab value. Alongside questions about energy, libido, and mood, a licensed clinician will also ask about urinary symptoms, prior prostate exams, and family history of prostate cancer. That's not incidental. Testosterone product labeling in the United States addresses the prostate directly: it states that testosterone therapy should not be used in men with known or suspected prostate cancer, because testosterone can fuel the growth of existing prostate tissue, including cancerous tissue.
This is patient education, not medical advice. Only an independent licensed medical professional can determine whether testosterone therapy, and what prostate monitoring around it, is appropriate for you.
Why prostate health is part of every TRT evaluation
Low testosterone and prostate health overlap for two reasons that have little to do with each other on the surface. First, both become more common with age, so the men considering TRT and the men at meaningfully higher prostate cancer risk are largely the same group. Second, and more directly relevant to a treatment decision, testosterone itself interacts with the prostate. The prostate gland is sensitive to androgens, and testosterone can act as fuel for prostate tissue growth, which is why product labeling contraindicates testosterone use in men with known or suspected prostate cancer.
That labeling point shapes how a responsible TRT evaluation is built. A thorough evaluation doesn't stop at confirming low testosterone on a blood test; it also looks for reasons testosterone therapy might be unsafe for a particular patient, and prostate cancer risk is one of the more consequential ones to rule out first.
You can read more about how a full evaluation is structured in our explainer on what testosterone replacement therapy is and who it's generally considered for.
What clinicians look for before starting: PSA and prostate screening
For many men, prostate screening as part of a TRT evaluation starts with a PSA (prostate-specific antigen) blood test. PSA is a protein produced by the prostate, and blood levels of it can rise for several reasons, including prostate cancer, but also benign prostatic hyperplasia (BPH, a non-cancerous enlargement of the prostate), prostatitis, and recent sexual activity. The Endocrine Society's clinical practice guideline on testosterone therapy recommends that clinicians discuss prostate cancer risk and consider a baseline PSA measurement before starting treatment in men for whom that risk is clinically relevant.
What a PSA test does, and doesn't, tell you
A PSA test is a screening tool, not a diagnosis. An elevated result doesn't mean prostate cancer is present, and a normal result doesn't rule it out completely. It's one data point that, combined with age, family history, symptoms, and sometimes a physical exam, helps a clinician decide whether further evaluation is warranted before or during testosterone therapy.
Depending on age, risk factors, and individual circumstances, a clinician may also ask about urinary symptoms, such as a weak stream, frequent urination, or waking at night to urinate. None of this is meant to be alarming. It's the kind of baseline screening many men eventually have as part of routine care; a TRT evaluation just tends to bring the conversation forward.
What the research says about testosterone therapy and prostate cancer risk
For decades, a widely held assumption in medicine was that testosterone essentially fed prostate cancer, an idea rooted in older research linking androgen suppression to prostate cancer treatment. More recent research has complicated that simple picture. Multiple studies in men without a prior prostate cancer diagnosis have not shown that testosterone therapy causes prostate cancer to develop, and professional guidance has shifted accordingly, though this remains an active area of ongoing study rather than a fully settled question.
What hasn't changed is the caution around existing, undetected disease. Because testosterone can accelerate the growth of prostate cancer that's already present, the concern isn't that TRT creates cancer from nothing; it's that starting testosterone in someone with an undiagnosed cancer could allow it to grow faster than it otherwise would. That distinction is exactly why screening before treatment, not just monitoring after, matters so much.
This nuance also explains why testosterone therapy in men with a personal history of treated prostate cancer is such an individualized decision, made only in close coordination between a urologist or oncologist and the prescribing clinician, well outside the scope of a routine online evaluation. For related safety considerations clinicians weigh during a TRT evaluation, see our explainer on testosterone therapy and cardiovascular risk.
Who needs extra caution before starting TRT
A few groups warrant a closer look before testosterone therapy starts:
- Known or suspected prostate cancer. Testosterone product labeling states it should not be used in men with known or suspected prostate cancer.
- An elevated or rising PSA without explanation. This generally calls for further urology evaluation before, not after, starting testosterone.
- Significant, unevaluated urinary symptoms. Because testosterone may worsen BPH-related symptoms, unexplained urinary changes are worth investigating first.
- Family history of prostate cancer. A first-degree relative with prostate cancer is an established risk factor that a clinician factors into how closely to screen.
- Black men. The NIH has documented that Black men have a higher lifetime risk of prostate cancer and are more likely to be diagnosed at a younger age, a pattern clinicians weigh when deciding how, and how often, to screen.
None of these automatically rules out testosterone therapy. They're reasons a clinician looks more closely, screens more deliberately, or in some cases refers for a urology evaluation before making a treatment decision.
Monitoring your prostate health during treatment
Screening before treatment starts is only the first half of how this risk is managed. Once testosterone therapy begins, periodic PSA testing and a review of urinary symptoms are typically part of ongoing monitoring, alongside the blood pressure and hematocrit checks covered in our guide to how TRT is prescribed and monitored. The exact schedule varies by clinician and by patient risk factors, but a PSA recheck in the months after starting therapy, followed by periodic rechecks, is a common approach.
A meaningful rise in PSA during treatment, not just a single elevated number, is often what prompts a closer look. Your clinician may recommend a repeat test, a referral to a urologist, or in some cases pausing testosterone therapy while the cause is investigated. This is a normal part of monitoring, not a sign that something has necessarily gone wrong.
New or worsening urinary symptoms after starting testosterone, such as a weaker stream, increased frequency, or trouble starting urination, are also worth reporting promptly rather than waiting for a scheduled follow-up.
Talking to your clinician about your personal risk
A few details are worth raising clearly during a TRT evaluation: your age, whether you've ever had a PSA test and what the result was, whether a parent or sibling has had prostate cancer, your race and ethnicity, and any urinary symptoms you've noticed, even mild ones. None of this information disqualifies you from treatment on its own. It helps your clinician build an accurate picture of your individual risk and decide what screening, if any, should happen before or alongside starting testosterone.
Starting an online evaluation does not guarantee a prescription. An independent licensed clinician reviews your health history, including any prostate-related risk factors, and determines what's appropriate for you. You can explore more of our clinician-reviewed testosterone therapy explainers, including our coverage of the signs and symptoms of low testosterone, or read about our editorial standards on the About the Journal page.
The bottom line
Testosterone therapy and prostate health are connected closely enough that product labeling contraindicates testosterone use in men with known or suspected prostate cancer. A thorough TRT evaluation typically includes prostate screening, often a PSA blood test, before treatment starts, along with ongoing monitoring afterward. None of this is meant to complicate a straightforward symptom; it's part of how testosterone therapy is prescribed and monitored responsibly, by a licensed clinician who looks at your full health picture, not just a single lab value.
Important Safety Information
Indication. Testosterone replacement therapy is FDA-approved to treat adult men with low testosterone caused by specific medical conditions that affect the testicles, pituitary gland, or brain and reduce the body's natural testosterone production; it is not FDA-approved simply for a decline in testosterone associated with aging alone.
Common side effects. Acne or oily skin, injection-site or application-site reactions, fluid retention, increased red blood cell count, and breast tenderness or enlargement have been reported.
Warnings. Testosterone product labeling states that testosterone should not be used in men with known or suspected prostate cancer or breast cancer, because testosterone may cause growth of existing prostate cancer. It may also worsen symptoms of benign prostatic hyperplasia and increase red blood cell counts requiring monitoring. Testosterone product labeling also describes a possible increased risk of heart attack and stroke, and states that testosterone therapy may worsen obstructive sleep apnea in some people. Topical testosterone products carry warnings about the potential for secondary exposure to testosterone in children and women through skin contact.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Does testosterone therapy cause prostate cancer?
Current evidence in men without a prior prostate cancer diagnosis has not shown that testosterone therapy causes prostate cancer to develop. The bigger concern is that testosterone could accelerate the growth of prostate cancer that's already present but undetected, which is why screening before treatment starts is part of a responsible evaluation.
Will I need a PSA test before starting TRT?
Many men have a PSA blood test as part of their evaluation, particularly when age or other risk factors make prostate cancer risk clinically relevant. Whether a PSA test, and how often, is appropriate for you is a decision your licensed clinician makes based on your individual health history.
Can I start testosterone therapy if I've had prostate cancer?
Testosterone product labeling states it should not be used in men with known or suspected prostate cancer. If you have a personal history of treated prostate cancer, this is a highly individualized decision that requires close coordination between a urologist or oncologist and the prescribing clinician, not something addressed through a routine online evaluation alone.
Does testosterone therapy affect an enlarged prostate (BPH)?
Testosterone may worsen urinary symptoms related to benign prostatic hyperplasia, a non-cancerous enlargement of the prostate. If you have significant, unevaluated urinary symptoms, your clinician will likely want those assessed before starting treatment.
What prostate monitoring happens once I'm on testosterone therapy?
Ongoing monitoring commonly includes periodic PSA testing and a review of urinary symptoms, alongside the other lab work used to track testosterone therapy. A meaningful rise in PSA or new urinary symptoms during treatment is something to report to your clinician promptly.
